Nearly half of the people with relapsing forms of multiple sclerosis (MS) treated early with Ocrevus (ocrelizumab) in Phase 3 clinical trials showed no evidence of disease activity after up to nine years on the therapy, data show. In contrast, about one-quarter of enrolled patients who started on…
AAN 2023
More than 80% of patients with relapsing forms of multiple sclerosis (MS) given Kesimpta (ofatumumab) continuously for up to five years in a clinical trial did not have any documented worsening of disability over the duration of the treatment. That’s according to new data from the ongoing…
There was no evidence of multiple sclerosis (MS) disease activity for at least two years in patients who underwent an autologous hematopoietic stem cell transplant (aHSCT) at a center in Mexico. And by the most recent follow-up — a median of about seven years after the procedure —…
More than 90% of Black and Hispanic patients with multiple sclerosis (MS) treated with Ocrevus (ocrelizumab) in a Phase 4 clinical trial experienced no new relapse activity or sustained disability worsening after nearly one year, according to an interim analysis. However, more than half of these patients experienced…
Treatment with Aubagio (teriflunomide) significantly reduces the risk that adults with radiologically isolated syndrome (RIS) will develop symptoms of multiple sclerosis (MS), new clinical trial data show. This is the second trial showing that approved disease-modifying therapies can delay the development of MS in people who have…
About 2.5 years of treatment with tolebrutinib was associated with low relapse rates and stable disability levels among people with relapsing forms of multiple sclerosis (MS), according to data in an ongoing, open-label extension of a Phase 2b trial. The oral treatment also continued to show a “favorable”…
Supplements with tauroursodeoxycholic acid (TUDCA) were generally well tolerated among people with progressive forms of multiple sclerosis (MS), according to findings from a small clinical trial. Results also showed that patients given TUDCA supplements had lower levels of certain inflammatory immune cells than those given a placebo, but no…
Use of the cell therapy MSC-NP failed to show a significant effect on overall disability scores among people with progressive forms of multiple sclerosis (MS), according to data from a Phase 2 clinical trial. Results, however, indicated that MSC-NP improved walking ability for people with more advanced disease —…
Most treatments for multiple sclerosis (MS) are not associated with an increased risk of complications during pregnancy, according to a new analysis. A few therapies were associated with slightly elevated rates of congenital abnormalities for babies exposed to treatment during pregnancy, but small sample sizes limit being able to…